WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017065497) ADENOVIRUS COMPLEX FOR GENE TRANSFER AND GENE THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/065497 International Application No.: PCT/KR2016/011437
Publication Date: 20.04.2017 International Filing Date: 12.10.2016
IPC:
A61K 35/761 (2015.01) ,A61K 38/00 (2006.01)
[IPC code unknown for A61K 35/761]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
Applicants: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY[KR/KR]; Hanyang Univ., 222, Wangsimni-ro, Seongdong-gu, Seoul 04763, KR
Inventors: YUN, Chae Ok; KR
NA, Youjin; KR
Agent: DANA PATENT LAW FIRM; 5th Floor, New Wing, Gwangsung Bldg., 11, Yeoksam-ro 3-gil, Gangnam-gu, Seoul 06242, KR
Priority Data:
10-2015-014243412.10.2015KR
Title (EN) ADENOVIRUS COMPLEX FOR GENE TRANSFER AND GENE THERAPY
(FR) COMPLEXE D'ADÉNOVIRUS POUR TRANSFERT GÉNÉTIQUE OU THÉRAPIE GÉNIQUE
(KO) 유전자 전달 및 유전자 치료를 위한 아데노바이러스 복합체
Abstract:
(EN) The present invention relates to an adenovirus complex which can be utilized for gene transfer and gene therapy by targeting neurotensin receptors. The complex of the present invention has an excellent antitumor effect because of a high intracellular gene transfer efficiency and target specificity by neurotensin receptor-specific binding, has little hepatotoxicity and immunogenicity, forms a stable complex, has low immunogenicity, and thus has a low loss in blood even in an in vivo environment. Therefore, the complex of the present invention can be effectively used for gene therapy.
(FR) La présente invention concerne un complexe d'adénovirus qui peut être utilisé pour un transfert génétique et une thérapie génique par ciblage de récepteurs de la neurotensine. Le complexe selon la présente invention a un excellent effet antitumoral en raison d'une excellente efficacité de transfert génétique intracellulaire et d'une grande spécificité de cible par liaison spécifique aux récepteurs de la neurotensine, présente de faibles hépatotoxicité et immunogénicité, forme un complexe stable, présente une faible immunogénicité, et ainsi une faible perte dans le sang, même dans un environnement in vivo. Par conséquent, le complexe selon la présente invention peut être utilisé efficacement en thérapie génique.
(KO) 본 발명은 뉴로텐신 수용체를 표적화하여 유전자 전달 및 유전자 치료에 활용할 수 있는 아데노바이러스 복합체에 관한 것으로, 본 발명의 복합체는 뉴로텐신 수용체 특이적 결합에 의한 세포내 유전자 전달 효율 및 타겟 특이성이 높아 우수한 항종양 효과를 가지면서도, 간독성 및 면역원성이 거의 없고, 안정한 복합체를 형성하고 면역원성이 낮아, 인비보 환경에서도 혈액 내에서 소실이 적어, 유전자 치료에 효과적으로 사용될 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)